5-Amino-1MQ
Small-molecule NNMT inhibitor studied in adipocyte and diet-induced obesity models.
73 compounds · 155 SKUs · every product ships as a box of 10 vials. Add what you need and send the list on Telegram.
Small-molecule NNMT inhibitor studied in adipocyte and diet-induced obesity models.
0.6% acetic acid solution for peptides that require a mildly acidic solvent.
Adamantane-conjugated research compound. Specification sheet available on request.
Sterile water with 0.9% benzyl alcohol for multi-dose lyophilized-peptide reconstitution.
Three repair mechanisms — cytoprotection, copper-peptide remodelling and actin-driven migration — in one vial.
The two most-studied repair peptides co-formulated 1:1.
Once-weekly amylin analogue studied alone and in combination with semaglutide (CagriSema).
Co-formulated amylin analogue and GLP-1 agonist in a single vial — the CagriSema research model.
Tetra-substituted GHRH(1-29) analogue for pulsatile GH-release research.
GHRH analogue plus selective secretagogue — the classic synergistic GH-release pairing.
Long-acting GHRH analogue: one dose, days of elevated GH and IGF-1.
Selective, long-acting amylin receptor agonist with 48-week phase 2 data.
Copper tripeptide with the anti-inflammatory α-MSH tripeptide.
Potent synthetic hexapeptide GH secretagogue, clinically used as a diagnostic agent.
The original synthetic GH-releasing hexapeptide that led to the discovery of ghrelin.
The primary intracellular antioxidant tripeptide — 1.5 g per vial.
The lipolytic C-terminal fragment of human growth hormone.
The first selective growth-hormone secretagogue — GH release without cortisol or prolactin.
The 10-residue active core of kisspeptin — the master upstream regulator of GnRH.
Four-peptide repair and anti-inflammatory co-formulation.
Lipolytic ampoule solution. Formulation sheet available on request.
Linear α-MSH analogue and approved drug (afamelanotide) for photoprotection research.
Cyclic superpotent α-MSH analogue with pigmentary and melanocortin-receptor activity.
The nine-residue neurohypophysial hormone — reproduction, social bonding and stress research.
Triple GIP / GLP-1 / glucagon receptor agonist — the next generation of incretin research.
Triple-agonist and amylin analogue co-formulated 1:1.
High-mass co-formulation of retatrutide and tirzepatide for combination-agonist studies.
Long-acting GLP-1 receptor agonist — the reference compound for incretin-based metabolic research.
The two Moscow regulatory heptapeptides co-formulated 1:1.
The native 29-residue active fragment of GHRH.
Glucagon / GLP-1 dual agonist in phase 3 for obesity and MASH.
Stabilised GHRH analogue with phase 3 evidence for visceral-fat reduction.
Stabilised GHRH analogue paired with the selective GHS-R agonist.
28-residue thymic peptide and approved immunomodulator with a comprehensive clinical literature.
Dual GIP and GLP-1 receptor agonist with the deepest weight-change effect of any approved incretin.